CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Charles River Laboratories International, Inc.

Stocks

CRL

US1598641074

Market Closed - NYSE Other stock markets 21:00:02 17/07/2026 BST			5-day change	1st Jan Change
224.35 ^USD	-2.10%		-3.88%	+12.47%

07-13	BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220	MT
07-13	Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating	MT

Transcript : Charles River Laboratories International, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 09

Published on 06/03/2026 at 04:35 pm BST - Modified on 06/03/2026 at 05:05 pm BST

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
David Windley (Analysts)

All right. While I get myself opened up here. Thank you for attending the conference. Good morning. I'm Dave Windley with Jefferies Healthcare Equity Research

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Charles River Laboratories International, Inc.

07-13	BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220	MT
07-13	Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating	MT
07-13	Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics	MT
07-13	Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches	CI
07-13	Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating	MT
07-09	Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220	MT
07-07	Evercore ISI Adjusts Price Target on Charles River Laboratories International to $260 From $220	MT
07-01	Charles River Laboratories International Insider Sold Shares Worth $16,875,000, According to a Recent SEC Filing	MT
07-01	Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating	MT
06-18	Charles River Laboratories International, Inc. and Eli Lilly and Company Enter Collaboration to Optimize Ai/Ml Platform Through Nonclinical Testing Expertise	CI
06-18	Rothschild & Co Redburn Adjusts Charles River Laboratories International PT to $241 From $230, Maintains Buy Rating	MT
06-17	Charles River Laboratories Shares Rise After Morgan Stanley Upgrade	MT
06-17	Morgan Stanley Upgrades Charles River Laboratories International to Overweight From Equal Weight, Adjusts PT to $220 From $185	MT
06-05	Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says	MT
06-03	Charles River Laboratories International, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 09:55 AM